

Characterization of *Salmonella enterica* Subsp. *enterica* Serovar 4,[5],12:i:- Clones Isolated from Human and Other Sources in Switzerland Between 2007 and 2011

Christine Gallati,¹ Roger Stephan,¹ Herbert Hächler,¹ Burkhard Malorny,²
Andreas Schroeter,² and Magdalena Nüesch-Inderbinnen¹

Abstract

Salmonella enterica subsp. *enterica* serovar 4,[5],12:i:- is a monophasic variant of *Salmonella* Typhimurium. In this study, a total of 651 human and 107 food and environmental isolates of serovar 4,[5],12:i:- recovered from 2007 through 2011 in Switzerland were characterized by antibiotic resistance profiles and pulsed-field gel electrophoresis (PFGE). In addition, a selection of isolates belonging to the most frequent PFGE patterns was further subjected to multilocus variable-number tandem-repeat analysis (MLVA) and phage typing. Over the years 2007–2011, the reports of salmonellosis caused by *Salmonella enterica* serovar 4,[5],12:i:- significantly increased. A high prevalence of multidrug-resistant isolates, mainly showing an ampicillin–streptomycin–sulfonamide–tetracycline resistance pattern (ASSuT), was observed. In addition, four extended spectrum beta lactamase (ESBL) (CTX-M-55)–producing isolates were found. *Xba*I PFGE analysis of all isolates revealed over 150 different pulsotypes, and generally showed a considerable diversity within the monophasic isolates. Nevertheless, among these we identified seven dominant profiles, which encompassed 66% of all isolates tested. The PFGE type STYMXB.0131 dominated among human as well as food isolates. Multilocus variable-number tandem-repeat analysis profile 3-12-10-0-0211, which, in many cases, coincided with PFGE type STYMXB.0131 and phage type DT193 were the most prevalent types found for the isolates further characterized by these typing methods. Our data provide strong evidence for a spread of two specific *Salmonella* serovar 4,[5],12:i:- clones (PFGE pattern STYMXB.0131, resistance type ASSuT) and (PFGE pattern STYMXB.0131, resistance type SSuT). In contrast to the human isolates, the pork/poultry isolates expressed predominantly the SSuT resistance type.

Introduction

NONTYPHOIDAL SALMONELLAE are often acquired from contaminated food, and they are an important cause of gastroenteritis and bacteremia, posing a worldwide threat to public health (Rabsch *et al.*, 2001). It is estimated that *Salmonella* causes 93.8 million human infections and 155,000 deaths annually worldwide (Majowicz *et al.*, 2010).

Since the year 2009, *S. enterica* subsp. *enterica* serovar 4,[5],12:i:- ranks among the three most frequent serovars found in Switzerland within the isolates submitted to the National Centre for Enteropathogenic Bacteria and Listeria for serotyping. It is known to be mainly a monophasic variant of *Salmonella* Typhimurium with antigenic and genotypic similarities (Echeita *et al.*, 2001). As with other enteric salmonellae, infections due to serovar 4,[5],12:i:- commonly manifest themselves as self-limiting gastroenteritis, but severe invasive infections can also occur, which call for antimicrobial

treatment. In those cases, fluoroquinolones, trimethoprim-sulfamethoxazole, ampicillin, or third-generation cephalosporins come into consideration (Hohmann, 2001). The emergence and spread of resistant bacteria and subsequent treatment failure is a significant and increasing global public health problem. A large proportion of the European serovar 4,[5],12:i:- strains is resistant to ampicillin, streptomycin, sulfonamides, and tetracycline, a resistance pattern (R-type) that is abbreviated by ASSuT (Hopkins *et al.*, 2010). The sources of isolates causing human infections often turned out to be pigs and pork products (Hauser *et al.*, 2010; Rodríguez *et al.*, 2012).

The objective of this study was to characterize human, food, and environmental isolates of serovar 4,[5],12:i:- collected from 2007 through 2011 in order to gain data about the epidemiology, phenotypic and genetic diversity, and susceptibility to antimicrobials of this serovar circulating in Switzerland. Such data provide a scientific basis for law-enforcement actions by food safety authorities.

¹Institute for Food Safety and Hygiene, Vetsuisse Faculty, University of Zurich, Zurich, Switzerland.

²Federal Institute for Risk Assessment, Biology Safety Department, National Reference Laboratory for *Salmonella*, Berlin, Germany.

Materials and Methods

Salmonella isolates

From 2007 through 2011, 8256 cases of *Salmonella* infection were reported to the Swiss Federal Office of Public Health. From this time span, 758 isolates of serovar 4,[5],12:i:- (651 from humans and 107 from food or environment [water] samples) were selected for this study. Most of the 651 human isolates were derived from stool samples. The remaining isolates originated from urine (11), blood (5), or other sites (44). More male (53.7%) than female cases (46.3%) were recorded. The average age for infection with *Salmonella* serovar 4,[5],12:i:- was 21 years (men: 19 years, women: 22 years). Multiple isolates from the same patient or isolates from family members were excluded. Nonhuman isolates ($N=107$) originated from pork ($N=71$), poultry ($N=22$), the environment ($N=8$), and for 6 isolates the origin was unknown. All samples had been collected and submitted to the National Centre for Enteropathogenic Bacteria and Listeria by diagnostic laboratories, hospitals, or family doctors throughout Switzerland.

Antibiotic susceptibility testing

The isolates were tested for antimicrobial susceptibility by the disk diffusion method according to the Performance Standards for Antimicrobial Susceptibility Testing (CLSI, 2008). The panel of antibiotic disks (Becton, Dickinson and Company, MD) consisted of ampicillin, amoxicillin/clavulanic acid, cephalothin, cefotaxime (CTX), ciprofloxacin, gentamicin, tetracycline, streptomycin, chloramphenicol, kanamycin, nalidixic acid, sulfamethoxazole, and trimethoprim. The strains were classified as resistant, intermediate, or susceptible to each antibiotic agent according to the CLSI criteria. For calculations of percentages, intermediate susceptibility was considered as resistant. Isolates displaying resistance to three or more antimicrobial compounds of different classes were defined as multidrug resistant.

Isolates whose resistance patterns demonstrated a synergy effect between amoxicillin/clavulanic acid and CTX in the disk diffusion test were further tested using E-Test extended spectrum beta lactamase (ESBL) strips (BioMérieux, Marcy l'Etoile, France) containing CTX, ceftazidime, or ceftazidime alone and in combination with clavulanic acid according to the manufacturer's protocols (Brown *et al.*, 2000). Confirmed ESBL producers were analyzed for *bla*_{TEM}, *bla*_{SHV}, and *bla*_{CTX-M} genes by polymerase chain reaction (PCR) and by sequencing the whole open reading frames of the responsible *bla* genes, using specific primer sets (Pitout *et al.*, 1998; Woodford *et al.*, 2006; Geser *et al.*, 2012). Resulting amplicons were purified using the PCR Purification Kit (Qiagen, Courtaboeuf, France) according to the manufacturer's recommendations. Custom sequencing was performed at Microsynth (Balgach, Switzerland) and the nucleotide and protein sequences were analyzed with Codon Code Aligner V. 3.7.1.1. For database searches, the BLASTN program of National Center for Biotechnology Information (<http://www.ncbi.nlm.nih.gov/blast/>) was used.

PFGE typing

Pulsed-field gel electrophoresis (PFGE) was performed using the restriction endonuclease *Xba*I (Roche, Mannheim, Germany) by following the Centers for Disease Control and Prevention (CDC) PulseNet protocol (<http://www.cdc.gov/>




FIG. 1. Percentage of human *Salmonella enterica* subsp. *enterica* serovar 4,[5],12:i:- isolates with the ampicillin-streptomycin-sulfonamide-tetracycline (ASSuT), streptomycin-sulfamethoxazole-tetracycline (SSuT), ampicillin-streptomycin-sulfonamide (ASSu) resistance patterns between 2007 and 2011.

pulsenet/protocols.htm). *Salmonella* serovar Braenderup strain H9812 (ATCC BAA 664) was used as reference strain. Gels were stained with ethidium bromide and visualized under ultraviolet light transillumination with Gel Doc (Bio-Rad, Munich, Germany). GelCompar II software (Applied Maths NV, Sint-Martens-Latem, Belgium) was used for analysis. Pairwise similarities between the *Xba*I PFGE patterns were calculated by the DICE similarity coefficient. Clustering was based on the unweighted pair-group method with averages, setting tolerance at 1% and optimization at 1.5%. The most frequent PFGE profiles were compared with profiles in the CDC PulseNet database and if possible assigned to reference strains of this database.

Multilocus variable-number tandem-repeat analysis (MLVA) and phage typing

Moreover, from the seven most frequent PFGE patterns, 40 isolates representing the genetic and antimicrobial resistance diversity were selected for MLVA and phage typing. MLVA was based on the protocol by Lindstedt *et al.* (2004) using an ABI 310 DNA Sequencer (Applied Biosystems, Darmstadt, Germany) (Beutlich *et al.*, 2011). For data evaluation, nomenclature according to Larsson *et al.* (2009) was used. Assignment of the phage type was done according to the Anderson typing scheme (Anderson *et al.*, 1977).

Results and Discussion

While the overall number of human salmonellosis cases in Switzerland decreased from 2001 to 2011, the number of

TABLE 1. RESISTANCE PATTERNS OF THE FOUR *bla*_{CTX-M-55} HARBORING *SALMONELLA ENTERICA* SUBSP. *ENTERICA* SEROVAR 4,[5],12:i:- ISOLATES

Strain	Resistance pattern	Travel history
N09-2591	A, S, Su, T, CF, CTX, G, C	Thailand
N09-2709	A, S, Su, CF, CTX, K, G, C	Thailand
N10-0857	A, S, Su, T, CF, CTX, C	None recorded
N11-0562	A, S, Su, T, CF, CTX, K, G	Thailand

isolates with serovar 4,[5],12:i:- increased during the last 8 years. In 2007, serovar 4,[5],12:i:- accounted for 5.8% (95% confidence interval [CI], 4.3; 7.6) of annual human *Salmonella* isolates. For the following years, those figures were as follows: 8.2% (95% CI, 6.7; 9.9) in 2008, 18.3% (95% CI, 15.9; 21.0) in 2009, 15.9% (95% CI, 13.6; 18.4) in 2010, and 18.2% (95% CI, 15.9; 20.7) in 2011, which was a significant change in the prevalence ($p < 0.05$).

A total of 327 isolates (43%) showed one to three resistances and 424 isolates (56%) displayed more than three resistances, whereas only seven isolates (1%) were fully susceptible against the antibiotics tested. During the years 2007–2011, the trend shifted toward the ASSuT resistance pattern (Fig. 1). The prevalence of ASSuT significantly increased from 35.4% (95% CI, 22.2; 50.5) to 53.7% (95% CI, 46.3; 60.9) among the human isolates ($p < 0.05$). We found 64% of all serovar 4,[5],12:i:- isolates resistant to ampicillin, 89% to streptomycin, 97% to sulfamethoxazole, and 88% to tetracycline while at most 6% of all isolates were resistant to any of the remaining nine antibiotics.

The second most frequent pattern was resistance against SSuT, with none recorded in 2007 and 24% detected in 2009 among human isolates. However, the SSuT pattern was found most frequently among the nonhuman isolates (about 70%). The third most common pattern included resistance against

ampicillin, sulfamethoxazole, and streptomycin (ASSu), and was found in about 7% of all human isolates tested, but never in nonhuman isolates.

Four human isolates expressed an ESBL phenotype (Table 1). The patients were 1, 22, and 23 years (two persons) of age. All four individuals lived in different cantons of Switzerland. These isolates were collected between 2009 and 2011. A comparison of their corresponding PFGE results showed different patterns for all four isolates (data not shown). They also differed from other serovar 4,[5],12:i:- *Xba*I PFGE patterns in Switzerland during this time period. PCR results revealed that all four isolates were positive for genes belonging to the TEM and the CTX-M families of β -lactamases. Sequencing of the entire open reading frames including flanking regions revealed the presence of *bla*_{TEM-1} and the ESBL gene *bla*_{CTX-M-55}. Three of the four affected patients had a history of travel to Thailand shortly before disease onset. For one patient, there was no recorded history of foreign travel. Interestingly, CTX-M-55 was first reported from Thailand (Kiratisin *et al.*, 2007), and—according to subsequent studies—remained endemic there. The fact that the four ESBL producers yielded various PFGE patterns despite the patients' similar anamnesis may well be explained by (1) the fact that ESBL genes in *Salmonella* are plasmid mediated and plasmids might spread independently to clonal spread of bacteria; (2) the long time period (3 years) during which they arose; and (3) the dynamics of the occurrence of *bla*_{CTX-M-55} in Thailand, a gene that was found there in *Klebsiella pneumoniae*, *Escherichia coli*, and also in *Salmonella* (Kiratisin *et al.*, 2007), implying association with transferable plasmids.

*Xba*I PFGE analysis of the 758 isolates revealed over 150 different pulsotypes, and generally showed a considerable diversity within the monophasic isolates. Nevertheless, among these we identified seven dominant profiles (Fig. 2), which encompassed 66% of all isolates tested. As many as 42% belonged to the PFGE-pattern STYMXB.0131 (Fig. 2, identification code A), 13% to STYMXB.0079 (code B), and 4%




FIG. 2. Dominant pulsed-field gel electrophoresis patterns (A–G) of *Salmonella enterica* subsp. *enterica* serovar 4,[5],12:i:- during the years 2007–2011 in Switzerland. Profiles D, F, and G could not be assigned with reference strains of CDC PulseNet database. This figure shows their next relatives (STYMXB.0080, STYMXB.0206, STYMXB.0330, STYMXB.0055, STYMXB.0301, STYMXB.0199). *Salmonella* Braenderup H9812 was used as reference strain. Clustering was based on the unweighted pair-group method with averages, setting tolerance at 1% and optimization at 1.5%.

TABLE 2. CHARACTERIZATION RESULTS OF 40 SELECTED *SALMONELLA ENTERICA* SUBSP. *ENTERICA* SEROVAR 4,[5],12:i:- ISOLATES FROM THE MOST COMMON PULSED-FIELD GEL ELECTROPHORESIS (PFGE) PROFILES

PFGE profile	Strain nr.	MLVA profile ^a	Phage type	Resistance pattern
Profile A (STYMXB.0131)	N08-1534 ^b	3-11-9-0-0211	DT 193	ASSuT
	N10-1394 ^b	3-12-10-0-0211	DT 193	ASSuT
	N08-1257 ^b	3-12-10-0-0211	DT 193	SSuT
	N08-2475 ^c	3-12-10-0-0211	DT 193	SSuT
	N10-0496 ^c	3-12-10-0-0211	DT 193	SSuT
	N10-2374 ^b	3-12-10-0-0211	DT 193	SSuT
	N11-0972 ^b	3-12-10-0-0211	DT 193	SSuT
	N11-1197 ^c	3-12-10-0-0211	DT 193	SSuT
	N09-2561 ^c	3-12-10-0-0211	RDNC ^d	SSuT
	N08-1933 ^e	3-13-10-0-0211	DT 193	ASSuT
	N07-0563 ^b	3-13-11-0-0211	DT 193	ASSuT
	N07-0096 ^b	3-13-9-0-0211	DT 193	ASSuT
	N09-0165 ^b	3-13-9-0-0211	DT 193	ASSuT
	N11-2679 ^b	3-13-9-0-0211	DT 193	ASSuT
	N09-0942 ^b	3-14-9-0-0211	DT 193	ASSu
Profile B (STYMXB.0079)	N10-1200 ^f	3-11-11-0-0211	DT 193	ASSuT
	N11-0988 ^b	3-12-10-0-0211	DT 104B _{low}	SuT
	N09-0920 ^b	3-12-10-0-0211	DT 193	ASSuT
	N08-0194 ^b	3-12-10-0-0211	U311	ASSuT
	N07-1933 ^b	3-13-10-0-0211	DT 193	ASSuT
	N10-2379 ^b	3-13-10-0-0211	U311	ASSuT
	N11-2063 ^b	3-13-10-0-0211	U311	ASSuT
	N08-1496 ^c	3-13-9-0-0211	DT 193	ASSuT
	N06-1830 ^c	3-13-9-0-0211	DT 7	SSuT
Profile C (STYMXB.0010)	N09-2019 ^b	3-14-8-0-0211	DT 104B _{low}	ASSuT-TMP
	N09-0946 ^b	3-12-10-0-0211	RDNC	SuT
	N08-0979 ^b	3-13-8-0-0211	DT 104B _{low}	ASSuT-TMP
	N08-1358 ^c	3-13-8-0-0211	DT 120	ASSuT-TMP
	N10-1923 ^b	3-13-9-0-0211	DT 104B _{low}	SSuT-TMP
	N11-0095 ^b	3-14-9-0-0211	RDNC	ASSuT
	N07-2375 ^b	3-8-9-0-0211	DT 120	SuT
Profile D	N07-1209 ^b	3-8-9-0-0211	U311	ASSuT
	N11-2663 ^b	3-14-9-0-0111	DT 193	ASSuT
Profile E (STYMXB.0083)	N10-2046 ^b	3-8-11-0-0211	DT 193	ASSuT
	N11-2388 ^b	3-11-9-0-0211	DT 104B _{low}	ASSuT
Profile F	N10-0984 ^b	3-12-10-0-0211	DT 104B _{low}	ASSuT
	N10-1142 ^b	3-13-8-0-0211	DT 193	ASSuT
Profile G	N11-1000 ^b	3-14-11-0-0211	DT 193	ASSuT
	N11-2499 ^b	3-12-10-0-0211	RDNC	ASSuT-G-C
	N11-1645 ^b	3-13-11-0-0211	RDNC	ASSuT

^aSTTR 9-5-6-10-3.^bHuman origin.^cFood origin (pork).^dReaction pattern did not conform to the phage scheme.^eFood origin (poultry).^fEnvironmental origin.

MLVA, multilocus variable-number tandem-repeat analysis; ASSuT, ampicillin–streptomycin–sulfonamide–tetracycline resistance pattern; SSuT, streptomycin–sulfamethoxazole–tetracycline resistance pattern; SuT, sulfamethoxazole–tetracycline resistance pattern; TMP, trimethoprim; G, gentamicin; C, chloramphenicol.

to STYMXB.0010 (code C) (Hopkins *et al.*, 2010). Patterns identified as codes D–G were found at rates below 3%. The frequency of STYMXB.0131 among the annual human serovar 4,[5],12:i:- isolates tested was 8.3% (95% CI, 2.3; 20.0) (4/48) in 2007 and reached a peak of 47% (95% CI, 39.3; 54.9) (79/168) in the year 2009. In contrast, the human STYMXB.0079 isolates represented 20.8% (95% CI, 10.5; 35.0) (10/48) of all human serovar 4,[5],12:i:- isolates in 2007 and decreased to 9.5% (95% CI, 5.5; 15.0) (16/168) in 2009. The human STYMXB.0010 isolates were found at a rate of 25% (12/48) in 2007 and de-

creased to 0.6% (95% CI, 0.01; 3.3] (1/168) in 2009. Patterns belonging to codes D–G showed no clear trend during this time period. It is worth mentioning that a considerable proportion, 118 of the 315 human ASSuT isolates (38%), was identified as STYMXB.0131, rendering this pulsotype the most frequent among the human isolates with the ASSuT resistance pattern. STYMXB.0131 strains in combination with this R-type were also frequently isolated in France, Germany, England, and Wales (Bone *et al.*, 2010; Hauser *et al.*, 2010; Hopkins *et al.*, 2010). Interestingly, STYMXB.0131 was also the

most prevalent pulsotype (60 of 71) among the monophasic pork isolates (Fig. 2). Moreover, 11 of the 22 poultry isolates belonged to this pulsotype (data not shown). In contrast to the human isolates—but in accordance with the pork isolates—the majority (7/11) of these poultry isolates expressed the SSuT resistance type, compared to only 2/11 showing the ASSuT. The *Salmonella* serovar 4,[5],12:i:- clone (PFGE pattern STYMXB.0131, resistance type SSuT) was isolated from humans as well as from pork/poultry meat, which gave strong evidence for an epidemiological link between pork/poultry meat and human disease. Of the 96 isolates belonging to the pulsotype STYMXB.0079, 52 corresponded to the ASSuT, and two to the SSuT resistance pattern. This pulsotype in combination with the R-type ASSuT was predominantly isolated from humans in Italy between 2003 and 2006 but not in other European countries (Dionisi *et al.*, 2009; Hopkins *et al.*, 2010). We speculate that this type was previously predominant in Switzerland and was replaced during the last several years by pulsotype STYMXB.0131.

Based on the seven most common PFGE patterns found, 40 isolates were selected for further characterization with MLVA and phage typing. The main focus was made on type STYMXB.0131, of which 15 isolates of different origins, dates of isolation, and resistance patterns were selected. From the second most frequently encountered PFGE pattern—STYMXB.0079—we chose 10 different isolates: from STYMXB.0010 seven isolates and from the remaining four patterns two isolates each.

Phage typing showed 10 different types with the following distribution: 55% (22/40) belonged to DT193, 15% (6/40) to DT104b_{low}, 12.5% (5/40) were RDNC (reaction pattern did not conform to the phage scheme), 10% (4/40) to U311, 5% (2/40) to DT120, and 2.5% (1/40) to DT7. Among the RDNC patterns, no commonality was found; therefore, they were counted as five different types. Again, these findings supported those reported earlier with the European 4,[5],12:i:- by Hopkins *et al.* (2010, 2012).

MLVA typing showed 13 different allele combinations (MLVA profiles), all of them with the same number of tandem repeats at locus STTR₉ and with absence of the virulence plasmid locus STTR₁₀ (Table 2). Differences were found at loci STTR₅, STTR₆, and STTR₃. Irrespective of the PFGE profile, resistance pattern, or phage type, the MLVA profile 3-12-10-0-0211 predominated with a percentage of 35% (14/40). As illustrated in Table 2, profile 3-13-9-0-0211 appeared in 15% (6/40) of the isolates, and no more than 10% of the isolates could be assigned to any other MLVA profile. Only one isolate with profile 3-14-9-0-0111 differed from the others at locus STTR₃. Locus STTR₃ with allele no. 0211 and locus STTR₉ with allele no. 3 were also typically found in other European serovar 4,[5],12:i:- isolates and, similarly, locus STTR₁₀ was consistently absent, indicating the lack of the typical *Salmonella* Typhimurium virulence plasmid in those isolates (Hauser *et al.*, 2010; Hopkins *et al.*, 2010). Loci STTR₅, STTR₆, and STTR₉ appear to be highly variable among the European and Swiss isolates.

Conclusions

In conclusion, *Xba*I PFGE analysis of all isolates revealed a large variety of profiles within the monophasic isolates. Nevertheless, among these we identified seven dominant profiles, which encompassed 66% of all isolates tested.

Moreover, our data provide strong evidence for a spread of two specific *Salmonella* serovar 4,[5],12:i:- clones (PFGE pattern STYMXB.0131, resistance type ASSuT) and (PFGE pattern STYMXB.0131, resistance type SSuT) during these years in Switzerland. In contrast to the human isolates, the pork/poultry isolates expressed predominantly the SSuT resistance type. The *Salmonella* serovar 4,[5],12:i:- clone (PFGE pattern STYMXB.0131, resistance type SSuT) was isolated from humans as well as from pork/poultry meat, which gives strong evidence for an epidemiological link between pork/poultry meat and human disease. Studies such as the one presented here are able to provide sufficient scientific data to act as grounds on which to base law-enforcement activities by food safety authorities. For example, the fact that an important percentage of the human morbidity is caused by one particular clone found in a particular and traceable product justifies such action. Nevertheless, the limitations are also clearly shown, in that other clones also contribute to morbidity. Hence, precise studies help in fine-tuning legal actions.

Acknowledgments

We thank Helga Abgottspon, Simon Bohli, Grethe Sägeser for their help in strain collection and for their technical support, Ernst Junker for his help with MLVA, and Katie Hopkins and Tansy Peters from CDC PulseNet for their support with comparison of PFGE patterns with the PulseNet database. This work was financially supported by the Swiss Federal Office of Public Health and by the Federal Institute for Risk Assessment, Germany, BFR46-003.

Disclosure Statement

No competing financial interests exist.

References

- Anderson ES, Ward LR, de Saxe MJ, de Sa JDH. Bacteriophage-typing designations of *Salmonella typhimurium*. J Hyg 1977; 78:297–300.
- Beutlich J, Jahn S, Malorny B, Hauser E, Hühn S, Schroeter A, Rodicio MR, Appel B, Threlfall J, Mevius D, Helmuth R, Guerra B. Antimicrobial resistance and virulence determinants in European *Salmonella* genomic island 1-positive *Salmonella enterica* isolates from different origins. Appl Environ Microbiol 2011;77:5655–5664.
- Bone A, Noel H, Le Hello S, Pihier N, Danan C, Raguenaud ME, Salah S, Bellali H, Vaillant V, Weill FX, Jourdan-da Silva N. Nationwide outbreak of *Salmonella enterica* serotype 4,12:i:- infections in France, linked to dried pork sausage, March–May 2010. Euro Surveill 2010;15:19592.
- Brown DF, Andrews J, King A, MacGowan AP. Detection of extended-spectrum β -lactamase with Etest and double-disc potentiation methods. J Antimicrob Chemother 2000;46:327–328.
- [CLSI] Clinical and Laboratory Standards Institute. Performance Standards for Antimicrobial Susceptibility Testing; Eighteenth Informational Supplement. CLSI document M100-S18 2008; Wayne, PA: Clinical and Laboratory Standards Institute, 2008.
- Dionisi AM, Graziani C, Lucarelli C, Filetici E, Villa L, Owczarek S, Caprioli A, Luzzi I. Molecular characterization of multidrug-resistant strains of *Salmonella enterica* serotype Typhimurium and monophasic variant (S. 4,[5],12:i:-) isolated from human infections in Italy. Foodborne Pathog Dis 2009;6:711–717.
- Echeita MA, Herrera S, Usera MA. Atypical, *fljB*-negative *Salmonella enterica* subsp. *enterica* strain of serovar 4,5,12:i:-

- appears to be a monophasic variant of serovar Typhimurium. J Clin Microbiol 2001;39:2981–2983.
- Geser N, Stephan R, Hächler H. Occurrence and characteristics of extended-spectrum β -lactamase-producing *Enterobacteriaceae* in food producing animals, minced meat and raw milk. BMC Vet Res 2012;7:21.
- Hauser E, Tietze E, Helmuth R, Junker E, Blank K, Prager R, Rabsch W, Appel B, Fruth A, Malorny B. Pork contaminated with *Salmonella enterica* serovar 4,[5],12:i:-, an emerging health risk for humans. Appl Environ Microbiol 2010;76:4601–4610.
- Hohmann EL. Nontyphoidal salmonellosis. Clin Infect Dis 2001;32:263–269.
- Hopkins KL, Kirchner M, Guerra B, Granier SA, Lucarelli C, Porrero MC, Jakubczak A, Threlfall EJ, Mevius DJ. Multi-resistant *Salmonella enterica* serovar 4,[5],12:i:- in Europe: A new pandemic strain? Euro Surveill 2010;15:19580.
- Hopkins KL, de Pinna E, Wain J. Prevalence of *Salmonella enterica* serovar 4,[5],12:i:- in England and Wales, 2010. Euro Surveill 2012;17:20275.
- Kiratisin P, Apisarnthanarak A, Saifon P, Laesripa C, Kitphati R, Mundy LM. The emergence of a novel ceftazidime-resistant CTX-M extended-spectrum β -lactamase, CTX-M-55, in both community-onset and hospital-acquired infections in Thailand. Diagn Microbiol Infect Dis 2007;58:349–355.
- Larsson JT, Torpdahl M, Petersen RF, Sorensen G, Lindstedt BA, Nielsen EM. Development of a new nomenclature for *Salmonella* Typhimurium multilocus variable number of tandem repeats analysis (MLVA). Euro Surveill 2009;14:19174.
- Lindstedt BA, Vardund T, Aas L, Kapperud G. Multiple-locus variable-number tandem-repeats analysis of *Salmonella enterica* subsp. *enterica* serovar Typhimurium using PCR multiplexing and multicolor capillary electrophoresis. J Microbiol Methods 2004;5:163–172.
- Majowicz SE, Musto J, Scallan E, Angulo FJ, Kirk M, O'Brien SJ, Jones TF, Fazil A, Hoekstra RM. The global burden of non-typhoidal *Salmonella* gastroenteritis. Clin Infect Dis 2010;50:882–889.
- Pitout JD, Thomson KS, Hanson ND, Ehrhardt AF, Moland ES, Sanders CC. β -lactamases responsible for resistance to expanded-spectrum cephalosporins in *Klebsiella pneumoniae*, *Escherichia coli*, and *Proteus mirabilis* isolates recovered in South Africa. Antimicrob Agents Chemother 1998;42:1350–1354.
- Rabsch W, Tschäpe H, Bäuml AJ. Non-typhoidal salmonellosis: Emerging problems. Microbes Infect 2001;3:237–247.
- Rodríguez I, Jahn S, Schroeter A, Malorny B, Helmutz R, Guerra B. Extended-spectrum β -lactamases in German isolates belonging to the emerging monophasic *Salmonella enterica* subsp. *enterica* serovar Typhimurium 4,[5],12:i:- European clone. J Antimicrob Chemother 2012;67:505–508.
- Woodford N, Fagan EJ, Ellington MJ. Multiplex PCR for rapid detection of genes encoding CTX-M extended-spectrum β -lactamases. J Antimicrob Chemother 2006;57:154–155.

Address correspondence to:

Roger Stephan, DVM
Institute for Food Safety and Hygiene
Vetsuisse Faculty, University of Zurich
Winterthurerstr. 272, CH-8057
Zurich, Switzerland

E-mail: stephanr@fsafety.uzh.ch